Skip to main content

Table 3 Response to GFIP/BDC

From: Use of a multi-drug regimen gemcitabine, 5-fluorouracil, irinotecan, cisplatin, bevacizumab, docetaxel, and cyclophosphamide (GFIP/BDC) for heavily pretreated relapsed epithelial ovarian, fallopian tube and primary peritoneal cancer

Response

No. of Patients

Percentage

Median Duration of Response (range)

Partial

11

55%

6 months (1.5 – 20)

Stable

7

35%

4.5 (2 – 6)

Progressive

2

10%

N/A